Andrew Thomas Crockett - CEO, Kalvista Pharmaceuticals, Inc
As of May 19, 2022
What is Andrew Thomas Crockett's Net Worth?
The current estimated net worth of Kalvista Pharmaceuticals, Inc's CEO, Andrew Thomas Crockett, is estimated to be about $5.37M . Andrew Thomas Crockett owns about 114,670 units of Kalvista Pharmaceuticals, Inc common stock. In the last 5 years at Kalvista Pharmaceuticals, Inc, Andrew Thomas Crockett has sold an estimated value of $3.27M worth.
What is Andrew Thomas Crockett's Past Insider Trading?
Andrew Thomas Crockett's largest sale order was 38,539 units , worth over $693.03K on October 22, 2020. In total, Andrew Thomas Crockett has made about 25 transactions over 5 years of their time at Kalvista Pharmaceuticals, Inc. Andrew Thomas Crockett usually trades in May, with the busiest year in 2021. The most recent transaction was a sale order of 10,000 units , worth over $170.69K on March 11, 2022.
Andrew Thomas Crockett
Ticker
|
Type
|
Value
|
Price per Share
|
Shares
|
Filing Date
| ||
|---|---|---|---|---|---|---|---|
| No matching records found | |||||||
What was Andrew Thomas Crockett's Salary in 2021?
As CEO of Kalvista Pharmaceuticals, Inc, Andrew Thomas Crockett has a total base salary of $556,120 . Andrew Thomas Crockett received compensation valued at about $2,308,027 in 2021 after becoming CEO. The vast majority of their compensation came in the form of a bonus of $458,799 , option awards of $1,281,708 , and other compensation of $11,400 .
What is Andrew Thomas Crockett's' Mailing Address?
- Mailing address is Building 227, Tetricus Science Park Porton Down, Salisbury Wiltshire X0 SP4 0JQ United Kingdom
Kalvista Pharmaceuticals, Inc Executive Compensation
Name |
Year
|
Salary
|
Bonus
|
Stock Awards
|
Option Awards
|
Other Compensation
|
Total
|
|---|---|---|---|---|---|---|---|
| T. Andrew Crockett | 2021 | $556,120 | $458,799 | - | $1,281,708 | $11,400 | $2,308,027 |
| T. Andrew Crockett | 2020 | $556,120 | $229,400 | - | $1,163,160 | $11,882 | $1,960,562 |
| T. Andrew Crockett | 2019 | $505,000 | $353,500 | - | $2,418,444 | $11,000 | $3,287,944 |
| Benjamin L. Palleiko | 2021 | $435,000 | $261,000 | - | $747,663 | $15,850 | $1,459,513 |
| Benjamin L. Palleiko | 2020 | $435,000 | $156,600 | - | $581,580 | $11,900 | $1,185,080 |
| Benjamin L. Palleiko | 2019 | $366,000 | $192,150 | $527,794 | $994,555 | $11,000 | $2,091,499 |
| Christopher M. Yea | 2021 | $420,000 | $252,000 | - | $712,060 | $25,341 | $1,409,401 |
| Christopher M. Yea | 2020 | $420,000 | $117,600 | - | $480,773 | $25,271 | $1,094,044 |
| Christopher M. Yea | 2019 | $341,093 | $174,596 | - | $891,350 | $20,466 | $1,427,505 |
| No matching records found | |||||||
Source: https://www.sec.gov/Archives/edgar/data/1348911/000119312521249158/d191826ddef14a.htm
What are Kalvista Pharmaceuticals, Inc's Past Insider Trades?
Kalvista Pharmaceuticals, Inc's most recent insider trade came on March 11, 2022 by Andrew Thomas Crockett who sold 10,000 units worth $170.69K . In the last 5 years, insiders at Kalvista Pharmaceuticals, Inc have sold an estimated value of $75.53M and bought an estimated value of $44.2M worth of shares. Insider trading is most common in October, with the busiest year in 2019 and 2021. The most active traders at the company are Andrew Thomas Crockett, CEO, Christopher Yea, Chief Development Officer, and Edward Feener, Chief Scientific Officer .
KalVista Pharmaceuticals, Inc. Insider Trades
Insider Names
|
Type
|
Value
|
Price per Share
|
Shares
|
Filing Date
| ||
|---|---|---|---|---|---|---|---|
| No matching records found | |||||||